These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 20162717)

  • 1. Circadian variation in radiation-induced intestinal mucositis in patients with cervical carcinoma.
    Shukla P; Gupta D; Bisht SS; Pant MC; Bhatt ML; Gupta R; Srivastava K; Gupta S; Dhawan A; Mishra D; Negi MP
    Cancer; 2010 Apr; 116(8):2031-5. PubMed ID: 20162717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral mucositis in morning vs. evening irradiated patients: a randomised prospective study.
    Goyal M; Shukla P; Gupta D; Bisht SS; Dhawan A; Gupta S; Pant MC; Verma NS
    Int J Radiat Biol; 2009 Jun; 85(6):504-9. PubMed ID: 19412843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3).
    Bjarnason GA; Mackenzie RG; Nabid A; Hodson ID; El-Sayed S; Grimard L; Brundage M; Wright J; Hay J; Ganguly P; Leong C; Wilson J; Jordan RC; Walker M; Tu D; Parulekar W;
    Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):166-72. PubMed ID: 18805649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy.
    Kouvaris J; Kouloulias V; Malas E; Antypas C; Kokakis J; Michopoulos S; Matsopoulos G; Vlahos L
    Strahlenther Onkol; 2003 Mar; 179(3):167-74. PubMed ID: 12627259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity.
    Kouloulias VE; Kouvaris JR; Pissakas G; Kokakis JD; Antypas C; Mallas E; Matsopoulos G; Michopoulos S; Vosdoganis SP; Kostakopoulos A; Vlahos LJ
    Strahlenther Onkol; 2004 Sep; 180(9):557-62. PubMed ID: 15378186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized clinical trial on continuous 7-days-a-week postoperative radiotherapy for high-risk squamous cell head-and-neck cancer: a report on acute normal tissue reactions.
    Suwinski R; Bankowska-Wozniak M; Majewski W; Sowa A; Idasiak A; Ziolkowska E; Windorbska W; Tarnawski R; Skladowski K; Maciejewski B
    Radiother Oncol; 2005 Oct; 77(1):58-64. PubMed ID: 16157401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of topical misoprostol to reduce radiation-induced mucositis: results of a randomized, double-blind, placebo-controlled trial.
    Veness MJ; Foroudi F; Gebski V; Timms I; Sathiyaseelan Y; Cakir B; Tiver KW
    Australas Radiol; 2006 Oct; 50(5):468-74. PubMed ID: 16981945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-reactive protein levels and radiation-induced mucositis in patients with head-and-neck cancer.
    Ki Y; Kim W; Nam J; Kim D; Park D; Kim D
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):393-8. PubMed ID: 19362778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: results of an IAEA multicentre randomised trial.
    Dobrowsky W; Huigol NG; Jayatilake RS; Kizilbash NI; Okkan S; Kagiya VT; Tatsuzaki H
    Radiother Oncol; 2007 Jan; 82(1):24-9. PubMed ID: 17161478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy.
    Tejwani A; Wu S; Jia Y; Agulnik M; Millender L; Lacouture ME
    Cancer; 2009 Mar; 115(6):1286-99. PubMed ID: 19170238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional hyperthermia combined with radiotherapy for uterine cervical cancers: a multi-institutional prospective randomized trial of the international atomic energy agency.
    Vasanthan A; Mitsumori M; Park JH; Zhi-Fan Z; Yu-Bin Z; Oliynychenko P; Tatsuzaki H; Tanaka Y; Hiraoka M
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):145-53. PubMed ID: 15629605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life and treatment related toxicity in 335 patients with locally advanced cervical carcinoma treated by two chemoradiation regimens.
    Nagy V; Todor N; Coza O; Ordeanu C; Ghilezan N
    J BUON; 2007; 12(3):389-94. PubMed ID: 17918294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application.
    Kouloulias VE; Kouvaris JR; Pissakas G; Mallas E; Antypas C; Kokakis JD; Matsopoulos G; Michopoulos S; Mystakidou K; Vlahos LJ
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):486-93. PubMed ID: 15890591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV infection and invasive cervical cancers, treatment with radiation therapy: toxicity and outcome.
    Shrivastava SK; Engineer R; Rajadhyaksha S; Dinshaw KA
    Radiother Oncol; 2005 Jan; 74(1):31-5. PubMed ID: 15683666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study.
    Chung YL; Jian JJ; Cheng SH; Hsieh CI; Tan TD; Chang HJ; Hung CF; Horng CF; Soong T; Tsou MH
    Gynecol Oncol; 2005 Apr; 97(1):126-35. PubMed ID: 15790448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation injury to intestine following hysterectomy and adjuvant radiotherapy for cervical cancer.
    Chen SW; Liang JA; Yang SN; Hung YC; Yeh LS; Shiau AC; Lin FJ
    Gynecol Oncol; 2004 Oct; 95(1):208-14. PubMed ID: 15385134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Radiation-induced mucositis and neutrophil granulocytes in oral mucosa].
    Schmidberger H; Rave-Fränk M; Kim S; Hille A; Pradier O; Hess CF
    Strahlenther Onkol; 2003 Oct; 179(10):667-72. PubMed ID: 14566474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: how well do physicians' assessments agree with those of their patients?
    Vistad I; Cvancarova M; Fosså SD; Kristensen GB
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1335-42. PubMed ID: 18355976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901.
    Ryu JK; Swann S; LeVeque F; Scarantino CW; Johnson D; Chen A; Fortin A; Pollock J; Kim H; Ang KK
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):643-50. PubMed ID: 17293228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.